Plain-English translation of NCT07380711 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of dupilumab in patients with chronic obstructive pulmonary disease (COPD) who have not responded well to standard treatments. Researchers want to understand how the medication works in everyday practice, who benefits most from it, and whether it remains safe over the long term. You would allow your medical records and health information to be tracked and studied over about three years.
Many people with COPD continue to struggle with severe symptoms and frequent flare-ups despite using standard inhalers. This study aims to learn whether this medication can help patients who haven't improved enough with current treatments, and to better understand real-world safety and how it affects quality of life.
You likely qualify if…
You likely don't qualify if…
You would continue taking the medication as prescribed by your doctor — participation does not involve taking anything new or changing your treatment plan. Instead, you would allow researchers to review your medical records, track how you're doing, and ask you to complete surveys about your symptoms and quality of life over the three-year study period. Your doctor will be managing your care normally; the study simply observes and documents what happens.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
France